File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Reducing influenza virus transmission: the value of antiviral treatment

TitleReducing influenza virus transmission: the value of antiviral treatment
Authors
Keywordsinfluenza
transmission
antiviral
baloxavir
oseltamivir
Issue Date2022
PublisherOxford University Press, published in association with Clinical Infectious Diseases. The Journal's web site is located at http://www.oxfordjournals.org/our_journals/cid/
Citation
Clinical Infectious Diseases, 2022, v. 74 n. 3, p. 532-540 How to Cite?
AbstractPrompt antiviral treatment has the potential to reduce influenza virus transmission to close contacts, but rigorous data on the magnitude of treatment effects on transmission are limited. Animal model data indicate that rapid reductions in viral replication after antiviral treatment reduce the risk of transmission. Observational and clinical trial data with oseltamivir and other neuraminidase inhibitors indicate that prompt treatment of household index patients seems to reduce the risk of illness in contacts, although the magnitude of the reported effects has varied widely across studies. In addition, the potential risk of transmitting drug-resistant variants exists with all approved classes of influenza antivirals. A controlled trial examining baloxavir treatment efficacy to reduce transmission, including the risk of transmitting virus with reduced baloxavir susceptibility, is currently in progress. If reduced transmission risk is confirmed, modeling studies indicate that early treatment could have major epidemiologic benefits in seasonal and pandemic influenza.
Persistent Identifierhttp://hdl.handle.net/10722/301643
ISSN
2021 Impact Factor: 20.999
2020 SCImago Journal Rankings: 3.440
PubMed Central ID
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorHayden, FG-
dc.contributor.authorAsher, J-
dc.contributor.authorCowling, BJ-
dc.contributor.authorHurt, AC-
dc.contributor.authorIkematsu, H-
dc.contributor.authorKuhlbusch, K-
dc.contributor.authorLemenuel-Diot, A-
dc.contributor.authorDu, Z-
dc.contributor.authorMeyers, LA-
dc.contributor.authorPiedra, PA-
dc.contributor.authorTakazon, T-
dc.contributor.authorYen, H-
dc.contributor.authorMonto, AS-
dc.date.accessioned2021-08-09T03:42:03Z-
dc.date.available2021-08-09T03:42:03Z-
dc.date.issued2022-
dc.identifier.citationClinical Infectious Diseases, 2022, v. 74 n. 3, p. 532-540-
dc.identifier.issn1058-4838-
dc.identifier.urihttp://hdl.handle.net/10722/301643-
dc.description.abstractPrompt antiviral treatment has the potential to reduce influenza virus transmission to close contacts, but rigorous data on the magnitude of treatment effects on transmission are limited. Animal model data indicate that rapid reductions in viral replication after antiviral treatment reduce the risk of transmission. Observational and clinical trial data with oseltamivir and other neuraminidase inhibitors indicate that prompt treatment of household index patients seems to reduce the risk of illness in contacts, although the magnitude of the reported effects has varied widely across studies. In addition, the potential risk of transmitting drug-resistant variants exists with all approved classes of influenza antivirals. A controlled trial examining baloxavir treatment efficacy to reduce transmission, including the risk of transmitting virus with reduced baloxavir susceptibility, is currently in progress. If reduced transmission risk is confirmed, modeling studies indicate that early treatment could have major epidemiologic benefits in seasonal and pandemic influenza.-
dc.languageeng-
dc.publisherOxford University Press, published in association with Clinical Infectious Diseases. The Journal's web site is located at http://www.oxfordjournals.org/our_journals/cid/-
dc.relation.ispartofClinical Infectious Diseases-
dc.rightsThis work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.-
dc.subjectinfluenza-
dc.subjecttransmission-
dc.subjectantiviral-
dc.subjectbaloxavir-
dc.subjectoseltamivir-
dc.titleReducing influenza virus transmission: the value of antiviral treatment-
dc.typeArticle-
dc.identifier.emailCowling, BJ: bcowling@hku.hk-
dc.identifier.emailDu, Z: zwdu@hku.hk-
dc.identifier.emailYen, H: hyen@hku.hk-
dc.identifier.authorityCowling, BJ=rp01326-
dc.identifier.authorityDu, Z=rp02777-
dc.identifier.authorityYen, H=rp00304-
dc.description.naturepublished_or_final_version-
dc.identifier.doi10.1093/cid/ciab625-
dc.identifier.pmid34245250-
dc.identifier.pmcidPMC8834654-
dc.identifier.scopuseid_2-s2.0-85124577993-
dc.identifier.hkuros323983-
dc.identifier.volume74-
dc.identifier.issue3-
dc.identifier.spage532-
dc.identifier.epage540-
dc.identifier.isiWOS:000754315700025-
dc.publisher.placeUnited States-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats